Obesity and cardiometabolic syndrome in children.
The cardiometabolic syndrome is highly prevalent among overweight youth. The risk of developing the cardiometabolic syndrome is likely triggered or exacerbated by concurrent obesity, unhealthy lifestyle/eating habits, and hormonal changes (puberty). Current screening recommendations include measurement of blood pressure, fasting insulin and glucose, and total cholesterol. However, limiting assessments to these measures underestimates cardiometabolic risk in overweight youth, particularly minorities. Early identification of cardiometabolic risk in its incipient stages may justify early and more aggressive intervention to prevent progression and complications. This review provides rationale for additional assessments to determine cardiometabolic risk in overweight youth and recommends treatment options.
Velasquez-Mieyer
Pedro
P
Dept. of Pediatrics, LeBonheur Children's Medical Center, 50 North Dunlap, Memphis, TN 38103, USA. pvelasquez@utmem.edu
Neira
Claudia P
CP
Nieto
Ramfis
R
Cowan
Patricia A
PA
D019440:Anti-Obesity Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000453:epidemiology*; D002648:Child; D050171:Dyslipidemias / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000453:epidemiology*; D009765:Obesity / Q000188:drug therapy / Q000453:epidemiology*; D015995:Prevalence; D012307:Risk Factors
D019440:Anti-Obesity Agents; D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents